Opioid Use Disorder Market Report 2024 (Global Edition)

Global Opioid Use Disorder Market Report 2024 Market Size Split by Drug Type (Buprenorphine, Naltrexone, Methadone), by Age Group (19 to 39, 40 to 59, Aged 60 and over), by Route of Administration (Or...

Opioid Use Disorder Market Report Description

We have various report editions of Opioid Use Disorder Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Opioid Use Disorder Market Insights Video

Competitive Landscape of the Opioid Use Disorder Market

The market for opioid use disorders (OUDs) is very competitive, with major manufacturers like Pfizer, Mallinckrodt, Alkermes, and Indivior holding a monopoly on well-known medication-assisted therapies (MATs) like naltrexone and buprenorphine. Innovative medicines and digital health solutions are the main focus of emerging firms. As the need for efficient OUD management options grows, competition is fueled by developments in treatment efficacy, regulatory approvals, and access expansion initiatives.

March 2023: The goal of Indivior PLC's acquisition of Opiant Pharmaceuticals, Inc. was to enhance the care of patients suffering from overdose or opioid addiction. With this acquisition, the company's position in the market was expected to increase. (Source:https://www.indivior.com/en/media/press-releases/indivior-completes-acquisition-of-opiant-pharmaceuticals-inc) February 2023: The U.S. FDA has received a new drug application (NDA) for Orexo AB's primary pharmaceutical pipeline candidate, OX124, a nasal rescue drug for opioid overdose. (Source:https://orexo.com/news-room/pressreleases-and-news/2023-02-03-orexo-submits-new-drug-application-to-fda-for-ox124-a-high-dose-rescue-medication-for-opioid-overdose) February 2021: ApexB.io, Magellan Rx Management, and Orexo AB worked together to research the application of Modia. Patients with opioid use disorder can benefit from a digital therapy called Modia. (Source:https://orexo.com/news-room/pressreleases-and-news/2021-02-10-orexo-starts-to-test-modia-on-patients-in-collaboration-with-apexb-io-and-magellan-rx-management) June 2020: Titan Pharmaceuticals, Inc. and Indegene have announced plans to expand their capacity to provide Buprenorphine implants for opioid-addicted patients and launch a multichannel digital marketing initiative in the United States. (Source:https://www.titanpharm.com/news/press-releases/detail/238/titan-pharmaceuticals-and-indegene-enter-into-probuphine-co-promotion-partnership)

Top Companies Market Share in Opioid Use Disorder Industry: (In no particular order of Rank)

• Indivior PLC
• Titan Pharmaceuticals
• Inc.
• Mallinckrodt Pharmaceuticals
• BioDelivery Sciences International Inc.
• Hikma Pharmaceuticals PLC
• Viatris Inc. (Mylan N.V.)
• Alkermes
• Orexo AB
• Camurus
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Opioid Use Disorder Market

Which Region Dominates the Opioid Use Disorder Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024. It accounted for around 40% of the global revenue. Because OUD is most common in this region, there is a considerable demand for treatment options. North America has a strong network of healthcare providers and treatment facilities, a sophisticated healthcare infrastructure, and substantial research and development resources. Furthermore, the development and dissemination of efficacious medicines are facilitated by strong regulatory frameworks and substantial funding for addiction treatment programs. North America's dominance in the OUD treatment industry is further attributed to the existence of top pharmaceutical companies and a strong emphasis on cutting-edge therapeutic techniques.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Opioid Use Disorder market. Because of growing awareness, a more extensive healthcare system, and an increase in OUD cases. To combat the epidemic, governments in the region are putting improved treatment programs and government initiatives into action. Market growth is being driven by continuous research and better access to efficient medicines. Furthermore, the Asia Pacific region's market is developing more quickly, and patient outcomes are increasing due to the rising partnerships between local and international organizations. These partnerships encourage innovation and better management techniques.

The current report Scope analyzes Opioid Use Disorder Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!

North America Opioid Use Disorder

According to Cognitive Market Research, the global Opioid Use Disorder market size was estimated at USD 2965.2 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 1186.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Opioid Use Disorder market with a market size of USD 935.82 million in 2024 and is projected to grow at a CAGR of 9.0% during the forecast period. Due to the severe opioid crisis and high rates of addiction in the country, there is a growing need for all-encompassing treatment solutions.
• The Canada Opioid Use Disorder market had a market share of USD 142.33 million in 2024 and is projected to grow at a CAGR of 10.0% during the forecast period. The market is driven by Canada's funding and supportive policies for addiction treatment, which include supervised consumption facilities.
• The Mexico Opioid Use Disorder market is projected to witness growth at a CAGR of 9.7% during the forecast period, with a market size of USD 107.93 million in 2024.

Europe Opioid Use Disorder

According to Cognitive Market Research, the global Opioid Use Disorder market size was estimated at USD 2965.2 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 889.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.5% from 2024 to 2031.

• The United Kingdom Opioid Use Disorder market had a market share of USD 149.45 million in 2024 and is projected to grow at a CAGR of 10.3% during the forecast period. The NHS's emphasis on expanding MAT availability and addiction treatment programs drives market expansion.
• The France Opioid Use Disorder market is projected to witness growth at a CAGR of 8.7% during the forecast period, with a market size of USD 81.84 million in 2024.
• According to Cognitive Market Research, the German Opioid Use Disorder market size was valued at USD 176.13 million in 2024 and is projected to grow at a CAGR of 9.7% during the forecast period. Comprehensive OUD treatments and services are supported by Germany's well-integrated healthcare system.
• The Italy Opioid Use Disorder market is projected to witness growth at a CAGR of 8.9% during the forecast period, with a market size of USD 76.50 million in 2024.
• The Russian Opioid Use Disorder market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 137.88 million in 2024.
• The Spain Opioid Use Disorder market is projected to witness growth at a CAGR of 8.6% during the forecast period with a market size of USD 72.94 million in 2024
• The Luxembourg Opioid Use Disorder market is projected to witness growth at a CAGR of 9.6% during the forecast period, with a market size of USD 27.58 million in 2024.
• The Portugal Opioid Use Disorder market is projected to witness growth at a CAGR of 9.3% during the forecast period, with a market size of USD 18.68 million in 2024.
• The Greece Opioid Use Disorder market is projected to witness growth at a CAGR of 9.8% during the forecast period, with a market size of USD 10.67 million in 2024.
• Rest of Europe's Opioid Use Disorder market is projected to witness growth at a CAGR of 8.2% during the forecast period, with a market size of USD 137.88 million in 2024.

Asia Pacific Opioid Use Disorder

According to Cognitive Market Research, the global Opioid Use Disorder market size was estimated at USD 2965.2 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 682.00 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Opioid Use Disorder market size was valued at USD 306.90 million in 2024 and is projected to grow at a CAGR of 12.5% during the forecast period. The need for OUD treatment options is rising in China as a result of a rise in the country's prescription opioid usage.
• The Japan Opioid Use Disorder market is projected to witness growth at a CAGR of 11.5% during the forecast period, with a market size of USD 94.12 million in 2024.
• The India Opioid Use Disorder market had a market share of USD 81.84 million in 2024 and is projected to grow at a CAGR of 14.8% during the forecast period. Growing opioid misuse, particularly in rural areas, is fueling the need for efficient treatment solutions.
• The South Korean Opioid Use Disorder market is projected to witness growth at a CAGR of 12.1% during the forecast period, with a market size of USD 68.20 million in 2024.
• The Australian Opioid Use Disorder market is projected to witness growth at a CAGR of 12.7% during the forecast period, with a market size of USD 35.46 million in 2024.
• The South East Asia Opioid Use Disorder market is projected to witness growth at a CAGR of 14.0% during the forecast period, with a market size of USD 47.06 million in 2024.
• The Rest of Asia Pacific's Opioid Use Disorder market is projected to witness growth at a CAGR of 12.8% during the forecast period, with a market size of USD 48.42 million in 2024.

South America Opioid Use Disorder

According to Cognitive Market Research, the global Opioid Use Disorder market size was estimated at USD 2965.2 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 148.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.4% from 2024 to 2031. .

• According to Cognitive Market Research, the Brazil Opioid Use Disorder market size was valued at USD 63.46 million in 2024 and is projected to grow at a CAGR of 11.0% during the forecast period. The need for OUD treatment programs is driven by concerns with drug use and urbanization.
• Argentina's Opioid Use Disorder market had a market share of USD 24.91 million in 2024 and is projected to grow at a CAGR of 11.3% during the forecast period. The market is growing as a result of initiatives to improve addiction services and the healthcare system.
• Colombia's Opioid Use Disorder market is projected to witness growth at a CAGR of 10.2% during the forecast period, with a market size of USD 13.20 million in 2024.
• Peru's Opioid Use Disorder market is projected to witness growth at a CAGR of 10.6% during the forecast period, with a market size of USD 12.16 million in 2024.
• Chile's Opioid Use Disorder market is projected to witness growth at a CAGR of 10.7% during the forecast period, with a market size of USD 10.67 million in 2024.
• The Rest of Latin America's Opioid Use Disorder market is projected to witness growth at a CAGR of 9.5% during the forecast period, with a market size of USD 23.87 million in 2024.

Middle East and Africa Opioid Use Disorder

According to Cognitive Market Research, the global Opioid Use Disorder market size was estimated at USD 2965.2 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 59.30 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.7% from 2024 to 2031..

• The GCC Countries Opioid Use Disorder market is projected to witness growth at a CAGR of 11.5% during the forecast period, with a market size of USD 25.38 million in 2024. Healthcare services and infrastructure are constantly being developed, which fuels market expansion.
• The Egypt Opioid Use Disorder market is projected to witness growth at a CAGR of 11.0% during the forecast period, with a market size of USD 6.23 million in 2024.
• The South African Opioid Use Disorder market is projected to witness growth at a CAGR of 11.7% during the forecast period, with a market size of USD 9.37 million in 2024. The market is growing as a result of government and non-governmental organizations' efforts to combat substance misuse.
• The Turkey Opioid Use Disorder market is projected to witness growth at a CAGR of 10.2% during the forecast period, with a market size of USD 5.10 million in 2024.
• The Nigeria Opioid Use Disorder market is projected to witness growth at a CAGR of 9.8% during the forecast period, with a market size of USD 6.23 million in 2024.
• The Rest of the MEA Opioid Use Disorder market is projected to witness growth at a CAGR of 9.7% during the forecast period, with a market size of USD 7.00 million in 2024.

Opioid Use Disorder Market Analysis

How are Segments Performing in the Global Opioid Use Disorder Market?

Opioid Use Disorder Market Drug Type Segment Analysis

According to Cognitive Market Research, buprenorphine stands out as the dominant category over the projected period. Because of its strong dual activity as a partial opioid agonist, it can effectively reduce cravings and withdrawal symptoms while lowering the risk of abuse and euphoria. Its ceiling impact lowers the danger of an overdose, and when used with naloxone, it further discourages abuse. Buprenorphine's adaptability improves patients' convenience and adherence in forms such as extended-release injectables and sublingual tablets. Treatment is more accessible because it doesn't require regular clinic visits like methadone does. Its established effectiveness in lowering opioid usage and promoting recovery confirms its important place in the treatment of OUD.

Naltrexone emerged as the fastest-growing category in the Opioid Use Disorder market. Owing to its special benefits. Because it completely blocks opioid receptors and eliminates the pleasurable effects of opioids, naltrexone, a full opioid antagonist, successfully prevents relapse. With monthly doses, the long-acting injectable form, Vivitrol improves patient adherence and lowers the chance of recurrence. When compared to other treatments, naltrexone is more appealing due to its non-addictive nature and low potential for abuse. Further driving its popularity and adding to its explosive market expansion are probably rising awareness and expanded insurance coverage.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Opioid Use Disorder Industry. Request a Free Sample PDF!

Opioid Use Disorder Market Age Group Segment Analysis

According to Cognitive Market Research, the dominant category is 19 to 39. Due to their propensity for greater rates of opioid addiction and misuse, people in the 19–39 age range are a crucial section of the market for opioid use disorder and abuse. Because of things like using prescription opioids for pain relief, using drugs recreationally, and dealing with stress from work and personal life, this age group is especially vulnerable. As a result, there is an increasing need for therapy programs that are specifically designed to meet the requirements of younger individuals, such as counseling and medication-assisted treatment (MAT). Effective intervention for OUD and a reduction in the overall burden of opioid addiction require addressing the unique problems that this age group faces.

The fastest-growing category in the Opioid Use Disorder market is 40 to 59. Because this age group frequently experiences chronic pain issues that result in prolonged opioid usage and possible misuse, the 40 to 59 age range constitutes a sizable portion of the Opioid usage Disorder (OUD) market. Due to the long-term use of prescription opioids for the management of pain from aging, injuries, or operations, people in this age group may be more susceptible to developing OUD. Treatment for OUD may also be more difficult in this age range due to a higher incidence of co-occurring health conditions. Comprehensive treatment alternatives, such as medication-assisted treatment (MAT), counseling, and support services catered to the unique requirements of middle-aged adults grappling with opioid addiction, are, therefore, in high demand.

The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Opioid Use Disorder market report 2024 Edition by contacting our team.

Opioid Use Disorder Route of Administration Segment Analysis

Opioid Use Disorder Market Route of Administration Segment Analysis

According to Cognitive Market Research, the dominant category is intravenous. The market for opioid use disorder (OUD) is heavily reliant on the intravenous (IV) route of delivery, especially in situations of severe OUD that demand immediate medical attention. Medication-assisted treatments (MAT) such as methadone or naloxone, which offer rapid relief from withdrawal symptoms or opioid overdoses, are frequently administered by IV in hospital settings. Because of its rapid bioavailability, this approach is crucial for detoxification and emergency treatment. However, because of its invasiveness and potential for consequences, it can only be used in restricted settings, usually with expert supervision. This has led to the OUD therapy industry becoming more specialized.

The fastest-growing category in the Opioid Use Disorder market is oral. Because it is the most practical and non-invasive approach, patient compliance and adherence are increased. Oral drugs, such as naltrexone and buprenorphine, are simpler to handle and administer because they don't need special tools or techniques. They also make it easy to include them in regular routines and provide customizable dosages. Oral drugs can also be taken at home, which eliminates the need for frequent clinic visits and increases patient comfort and accessibility. Oral formulations have a well-established track record of successfully controlling OUD, and their widespread availability and ease of administration further solidify their prominent position in the treatment landscape.

• Oral
• Intravenous

Opioid Use Disorder Distribution Channel Segment Analysis

Opioid Use Disorder Market Distribution Channel Segment Analysis

According to Cognitive Market Research, the dominant category is hospital pharmacy. Because they are essential to the management of severe and complex cases. They provide a safe, regulated setting in which drugs can be given under close supervision, which is essential for guaranteeing safety and adherence, especially for injectable and high-risk medicines. Additionally, hospital pharmacists offer complete patient care, which boosts the effectiveness of treatment and aids in recovery. This care includes counseling and monitoring. Their dominance in the provision of OUD therapies is bolstered by their capacity to coordinate care with other healthcare services and manage and supply specialist drugs, such as methadone and extended-release formulations. Their popularity in the distribution route is driven by their crucial role in patient care and safety.

The fastest-growing category in the Opioid Use Disorder market is mass retail pharmacy. Because they provide easy access to drugs like buprenorphine and naltrexone, retail pharmacies are essential to the treatment of opioid use disorder (OUD). Patients can fill prescriptions at their handy locations, and their counseling services serve to ensure that patients follow their treatment plans. Because of their accessibility and community reach, these pharmacies are critical to public health initiatives focused on addressing the opioid crisis. These initiatives will improve patient outcomes in OUD care and treatment availability.

• Hospital Pharmacy
• Retail Pharmacy

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion